Company Filing History:
Years Active: 2010-2011
Title: Innovator Keting Chu: Pioneering Antibody Research
Introduction: Keting Chu, based in Hillsborough, CA, is a prominent inventor with a focus on advancing medical science through his innovative research on antibodies. With a total of two patents to his name, Chu's work plays a crucial role in developing treatments for various diseases.
Latest Patents: Keting Chu's latest patents include significant advancements in the field of stromal cell-derived factor-1 (SDF-1) polypeptides. One patent details a newly identified SDF-1 splice variant molecule, including its polypeptide sequence and the polynucleotides that encode this sequence. Additionally, it outlines a procedure for producing these polypeptides using recombinant techniques, such as vectors and host cells. The implications of this research extend to utilizing these polypeptides and their modulators for treating diseases such as cancer, immune diseases, infectious diseases, and ischemic diseases.
Career Highlights: Keting Chu is currently affiliated with Five Prime Therapeutics, Inc., where he contributes to innovative biotechnology solutions. His patents reflect his commitment to addressing complex medical challenges through scientific exploration and technology.
Collaborations: Throughout his career, Keting Chu has collaborated with esteemed colleagues including Lewis T. Williams and Justin G. P. Wong. Together, they share a vision of advancing therapeutic options through their combined expertise, driving meaningful progress in healthcare.
Conclusion: Keting Chu’s innovative contributions to the research of antibodies showcase the potential for enhancing treatment options for serious health conditions. His patents and collaborative efforts highlight the importance of continued research and development in the biomedical field, making strides toward a healthier future.